The tweet was deleted by the author.
But we saved everything 🙂.
TempusAI has reported its financial results for the quarter ending March 31, 2026.
Eric Lefkofsky announced the quarterly performance and shared additional perspective in a new letter, offering context on the reported results. He highlighted TempusAI's continued advantage in scaling precision medicine for physicians and patients, focusing on the advancement and accessibility of tailored healthcare solutions. The full letter provides further information on TempusAI's approach and the company's outlook for the rest of the year.
Earlier this year, Eric Lefkofsky highlighted the delivery of 31 scientific abstracts at AACR26 focused on patient care innovation. He has also recognized the role of lab professionals in delivering precise genomic sequencing and analysis. These efforts align with TempusAI’s ongoing emphasis on applying advanced data to improve healthcare outcomes.